Liver Transplantation for Hepatocellular Carcinoma: A Single Center Resume Overlooking Four Decades of Experience

Figure 7

Survival with respect to tumor morphology and neoadjuvant therapy. Hospital mortality and non-HCC recurrence related deaths as well as treatment groups with were excluded. In the category of nondetectable tumors only surgery remained with . The cumulative survival in this subcategory was 80% (a). In the category of uninodular HCC (b) there was no difference in survival comparing patients that had been pretreated by PEI or TACE. For the combination of PEI and TACE a significantly better survival was observed (Log Rank ) as compared to PEI or TACE alone. For multinodular/unilateral HCC (c) TACE did not make a difference, while pretreatment with PEI achieved a significant better survival (Log Rank ). In multinodular/bilateral tumors (d) survival was significantly better for the group of patients who were pretreated with TACE as compared to PEI or no pretreatment.

(a)

(b)

(c)

(d)